Figure 1



N - EGF C1 C2 SD - C
N - SD EGF C1 C2 - C
N - EGF SD C1 C2 - C
N - EGF C1 SD C2 - C
N - C1 C2 SD EGF - C
N - C1 SD C2 EGF - C

Figure 2

Fig 2A:
EGF-HSA-C1-C2
(FP330)




Fig 2B:
EGF-HSA-C1-C2 of EDIL3
(FP050)




Fig 2C:
EGF-Fc(KiH)-C1-C2
non-reduced and reduced
(FP071 + Fc-IgG1 (hole))




Fig 2D:
EGF-HSA-C1
(FP260)





Fig 2E: SDS-PAGE analysis of truncated MFG-E8, HSA fusions and MFG-E8/EDIL-3 chimeric proteins




Line 1, 12:	Molecular weight marker (Biorad, Precision plus protein)		
Line 2:	His6_EGF[MFG-E8]_C1[MFG-E8]		23.87kDa
Line 3:	EGF[MFG-E8]_C1[MFG-E8]_His6	SEQ ID 115	23.87kDa
Line 4:	EGF[MFG-E8]_HSA_C1[MFG-E8]	SEQ ID 117	90.38kDa
Line 5:	EGF[MFG-E8]_HSA_C1[MFG-E8]	SEQ ID 74	89.27kDa
Line 6:	EGF[MFG-E8]_HSA_C1[MFG-E8]	SEQ ID 73	88.72kDa
Line 7:	EGF[EDIL3]_HSA_C1[EDIL3]	SEQ ID 71	98.22kDa
Line 8:	EGF[EDIL3]_HSA_C2[EDIL3]	SEQ ID 135	98.20kDa
Line 9:	EGF[MFG-E8]_HSA_C2[MFG-E8]	SEQ ID 137	88.45kDa
Line 10:	EGF[EDIL3]_HSA_C1_C2[MFG-E8]	SEQ ID 80	115.67kDa
Line 11:	EGF[MFG-E8]_HSA_C1_C2[EDIL3]	SEQ ID 82	107.32kDa

Figure 3


WT MFG-E8 (EGF-C1-C2)

Fig 3A



FP278 (EGF-HSA-C1-C2-His tag)

Fig 3B






Figure 4

Fig 4A




Fig 4B




Figure 5

Fig 5A




Fig 5B




Fig 5C



FP250
FP330
5000000
4000000
3000000
2000000
1000000
0
Cell adhesion (AU)
0.01
0.1
1
10
100
immobilized protein (nM)

Fig 5D



FP330 (expressed in CHO)
FP330 (expressed in HEK)
wtMFG-E8
1×10 7
8×10 6
6×10 6
4×10 6
2×10 6
0
Cell adhesion (AU)
0.01
0.1
1
10
100
immobilized protein (nM)

Figure 6



Efferocytosis Index %
55
50
45
40
35
30
EC50: 4.5 nM
basal efferocytosis
10-2
10-1
100
101
102
103
FP278 [nM]

Figure 7

Fig 7A




Fig 7B




Figure 8

Fig 8A




Fig 8B




Figure 9




Figure 10




Figure 11

Fig 11A




Fig 11B




Fig 11C




Fig 11D





FP050
(EDIL3 based EGF-EGF-EGF-HSA-C1-C2)
Efferocytosis [MFI]
2500
2000
1500
1000
500
0
10-2
10-1
100
101
102
[nM]


Fig 11E


MFG-E8
MFG-E8
EGF
HSA
C1
RGD
FP114/FP260
EDIL3
EDIL3
EGF
EGF
EGF
HSA
C1
RGD
FP147/FP1777
MFG-E8
EDIL3
EGF
HSA
C1
RGD
FP1149
EDIL3
MFG-E8
EGF
EGF
EGF
HSA
C1
RGD
FP1150
EDIL3
MFG-E8
EGF
EGF
EGF
HSA
C1
C2
RGD
FP145
MFG-E8
EDIL3
EGF
HSA
C1
C2
RGD
FP146
EDIL3
MFG-E8
EGF
HSA
C1
C2
RGD
FP1145
EDIL3
MFG-E8
EGF
HSA
C1
C2
RGD
FP1146
MFG-E8
or EDIL3
TIM-4
EGF
HSA
IgSF
V
RGD
FP1147
MFG-E8
or EDIL3
GAS6
EGF
HSA
GLA
RGD
FP1148


Fusion protein comprising domains of GAS6/PROS1



Fusion protein comprising domains of Factor VIII (Modified Turoctocog alfa)



Schematic representation of a recombinant fusion protein example comprising domains of thrombomodulin (CD141)



Schematic representation of a recombinant fusion protein example comprising domains of Complement component C1q receptor (CD93)




Figure 12



Efferocytosis
[MFI]
3000
2000
1000
0
No Protein
0.3 nM
3 nM
30 nM
+ FP278

Figure 13

Fig 13A




Fig 13B




Fig 13C




Fig 13D




Fig 13E



FP147
Efferocytosis Index %
60
50
40
30
20
EC50 2 nM
10-2
10-1
100
101
102
103
conc (nM)

Figure 14

Fig 14A




Fig 14B




Fig 14C




Figure 15

Fig 15A




Fig 15B




Fig 15C




Figure 16




Figure 17

Fig 17A




Fig 17B




Figure 18




Figure 19




Figure 20

Liver stiffness assessed by Shear Wave Elastography




Fig 21A




Fig 21B




Fig 21C



COL1A1 expression in liver
α-1 type I collagen
Relative expression
(arbitrary control ΔCt=15 - GAPDH as endog. ctrls)
* p=0.025
20000
15000
10000
5000
0
naive
vehicle
PBS 10ml/Kg i.p
FP135 4 doses
FP135 8 doses
FP135 11 doses
COL1A2 expression in liver
α-2 type I collagen
Relative expression
(arbitrary control ΔCt=15 - GAPDH as ctrls)
* p=0.03
4000
3000
2000
1000
0
naive
vehicle
PBS 10ml/Kg i.p
FP135 4 doses
FP135 8 doses
FP135 11 doses

Figure 22




Figure 23 Hydrodynamic radius of EGF-C1 and EGF-HSA-C1 measured at 3mg/mL in PBS, pH7.4 upon thermal stress

